ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs

Dec 09, 2022

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them.

The 64th ASH Annual Meeting and Exposition is a four-day premier event in malignant and non-malignant hematology, scheduled to start on December 10, 2022. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few major abstracts for diffuse large B-cell lymphoma (DLBCL).

The key abstracts have been summarized in the table below:

Downloads

Article in PDF

Recent Articles

Pirtobrutinib Monotherapy: A Promising Beacon of Efficacy and Safety in Relapsed/Refractory Folli...

Parkinson’s and Tuberculosis Share a Common Protein That Could Provide Better Drugs for Both

A Glance at Key Insights From 42nd J.P. Morgan Annual Healthcare Conclave

Major Highlights of Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) in ASH 2021

Most Promising Oncological Drugs Expected to Launch in 2022

Drug regimen	Abstract ID	Abstract Title	Trial ID	Company	Class
Tafasitamab + Lenalidomide + R-CHOP	2947	Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma	NCT04824092 (frontMIND)	MorphoSys AG	CD19-directed monoclonal antibody
Odronextamab	444	Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2	NCT03888105 (ELM-2)	Regeneron Pharmaceuticals	Bispecific antibody
Loncastuximab Tesirine + Rituximab	2955	A Phase II, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)	NCT05144009 (LOTIS-9)	ADC Therapeutics	Antibody Drug Conjugate (ADC)
Epcoritamab + R-DHAX/C	443	Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase I/II Results	NCT04663347 (EPCORE NHL-2)	Genmab/AbbVie	Bispecific antibody
Mosunetuzumab	738	Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma	NCT03677154	Roche	Bispecific antibody
Axicabtagene Ciloleucel + Lenzilumab	4635	ZUMA-19: A Phase I/II Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma	NCT04314843 (ZUMA-19)	Gilead Sciences	CAR-T cell therapy
Iberdomide ± Anti-CD20	233	Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase I/II Study	NCT04464798	BMS	Immunomodulatory imide drug (IMiDs)
Tafasitamab + Lenalidomide + R‑CHOP	1619	First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma	NCT04134936 (First-MIND)	MorphoSys AG	CD19-directed monoclonal antibody
Glofitamab + R-CHOP	737	Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study	NCT03467373	Roche	Bispecific antibody
YTB323	439	YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update	NCT03960840	Novartis Pharmaceuticals	CAR-T cell therapy